Coeptis Therapeutics (NASDAQ:COEP) Trading Up 2.8% – What’s Next?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP)’s share price was up 2.8% during trading on Tuesday . The company traded as high as $12.44 and last traded at $12.44. Approximately 23,743 shares were traded during trading, a decline of 53% from the average daily volume of 50,972 shares. The stock had previously closed at $12.10.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Coeptis Therapeutics currently has an average rating of “Sell”.

Coeptis Therapeutics Stock Performance

The company has a 50 day moving average price of $11.84 and a 200-day moving average price of $13.98. The company has a current ratio of 4.16, a quick ratio of 4.16 and a debt-to-equity ratio of 0.01. The company has a market cap of $85.28 million, a P/E ratio of -4.60 and a beta of -0.44.

Coeptis Therapeutics (NASDAQ:COEP) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative net margin of 803.96% and a negative return on equity of 110.89%. The business had revenue of $0.86 million during the quarter.

Institutional Investors Weigh In On Coeptis Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC grew its position in Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the last quarter. Geode Capital Management LLC grew its position in Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the last quarter. State Street Corp grew its position in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the last quarter. Yorkville Advisors Global LP bought a new stake in Coeptis Therapeutics during the 3rd quarter worth $140,000. Finally, Marshall Wace LLP bought a new stake in Coeptis Therapeutics during the 4th quarter worth $259,000. Institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.